Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06237296 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
A Phase 1 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 558
- Enrollment target
NCT06237296 is a Phase 1 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 558 participants.
The verdict
NCT06237296, a Phase 1 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 558 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) and/or human metapneumovirus (hMPV) in older adults. A single intramuscular (IM) injection of 3 to 4 different doses of the RSV/hMPV mRNA vaccine candidate formulated with 2 different lipid nanoparticles (LNP) will be administered to healthy participants aged 18 to 49 years and 60 years and older. Treatment: * RSV/hMPV mRNA / LNP 1 at 3-4 different doses or, * RSV/hMPV mRNA / LNP 2 at 3-4 difference doses or, * RSV mRNA / LNP 1 at 1 dose or, * hMPV mRNA / LNP 1 at 1 dose
Interventions
- BIOLOGICAL RSV/hMPV mRNA LNP 1
- BIOLOGICAL RSV/hMPV mRNA LNP 2
- BIOLOGICAL RSV mRNA LNP 1
- BIOLOGICAL hMPV mRNA LNP 1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2025-02-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06237296
The ClinicalTrials.gov registry entry for NCT06237296 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which RSV/hMPV mRNA LNP 1 is the first listed.
NCT06237296 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06237296 about?
NCT06237296 is a clinical study titled "Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older". The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) and/or human metapneumovirus (hMPV) in older adults. A single i...
What is the current status of trial NCT06237296?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 558 participants. The study started on 2024-01-23. Estimated completion is 2025-02-11.
What interventions are being tested in trial NCT06237296?
The interventions under investigation include: RSV/hMPV mRNA LNP 1 (BIOLOGICAL), RSV/hMPV mRNA LNP 2 (BIOLOGICAL), RSV mRNA LNP 1 (BIOLOGICAL), hMPV mRNA LNP 1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06237296?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.